Updated Jul 16, 2026
Pelish Henry E. has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $9.30M.
Henry E. Pelish is the Chief Scientific Officer at Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on targeted cancer therapies. He has been involved in the company's development of small molecules aimed at overcoming limitations of existing cancer treatments.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-15 | NUVL | Nuvalent, Inc. | D — Derivative transaction | 14.3K | — | |
| 2026-07-15 | NUVL | Nuvalent, Inc. | A — Grant or award | 14.3K | $0.00 | |
| 2026-07-15 | NUVL | Nuvalent, Inc. | D — Derivative transaction | 41.1K | — | |
| 2026-07-15 | NUVL | Nuvalent, Inc. | J — Other acquisition / disposition | 22.4K | $124.00 | $2.78M |
| 2026-07-10 | NUVL | Nuvalent, Inc. | S — Open-market sale | 2.1K | $123.81 | $261K |
| 2026-04-13 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 900 | $105.00 | $94K |
| 2026-04-13 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 2.2K | $104.27 | $229K |
| 2026-04-13 | NUVL | Nuvalent, Inc. | M — Option exercise [10b5-1] | 3.1K | $27.85 | $86K |
| 2026-03-16 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 1.7K | $99.71 | $170K |
| 2026-03-16 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 2.6K | $98.83 | $257K |
| 2026-03-16 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 804 | $97.89 | $79K |
| 2026-03-16 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 306 | $99.12 | $30K |
| 2026-03-16 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 5.5K | $98.44 | $542K |
| 2026-03-16 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 24.2K | $97.79 | $2.37M |
| 2026-03-16 | NUVL | Nuvalent, Inc. | M — Option exercise [10b5-1] | 3.0K | $72.35 | $216K |
| 2026-03-16 | NUVL | Nuvalent, Inc. | M — Option exercise [10b5-1] | 4.1K | $29.33 | $121K |
| 2026-03-16 | NUVL | Nuvalent, Inc. | M — Option exercise [10b5-1] | 1.8K | $27.85 | $49K |
| 2026-03-16 | NUVL | Nuvalent, Inc. | M — Option exercise [10b5-1] | 8.5K | $18.93 | $160K |
| 2026-01-07 | NUVL | Nuvalent, Inc. | A — Grant or award [10b5-1] | 17.5K | $0.00 | |
| 2026-01-07 | NUVL | Nuvalent, Inc. | S — Open-market sale [10b5-1] | 189 | $98.40 | $19K |
Henry E. Pelish is the Chief Scientific Officer at Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on targeted cancer therapies. He has been involved in the company's development of small molecules aimed at overcoming limitations of existing cancer treatments.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 28 open-market sales ($9.30M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Pelish Henry E. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.